Investments, Funding & Disinvestment

The facility is built to accommodate approximately 1,000 to 1,500 healthcare professionals each year, including consultants, specialists, and early-career doctors.

The JV combines Arna Pharma’s formulation development expertise and portfolio expansion strategy with Slate Run Pharmaceuticals’ established US commercial operations, regulatory capabilities, and supply chain infrastructure.

Cellular Intelligence plans to continue the clinical development of the Parkinson’s therapy using its proprietary artificial intelligence platform, which is designed to optimize cell therapy manufacturing and accelerate development timelines.

Through this acquisition, the company strengthens its ability to support cell therapy developers with integrated manufacturing, processing, and cryopreservation services under a unified platform.

Isomorphic Labs plans to use the new capital to further develop and deploy its proprietary AI drug design engine, known as IsoDDE.

The acquisition will give Zydus access to Assertio’s commercial infrastructure in the US specialty pharmaceutical market, particularly in oncology supportive care and pain management therapies.

The approval applies to adolescents and adults weighing at least 35 kilograms who have haemophilia A with factor VIII inhibitors or haemophilia B with factor IX inhibitors.

The acquisition includes MacroGenics’ biologics drug substance manufacturing facility in Rockville, Maryland, as well as a warehousing center in Frederick, Maryland, located about 30 miles away.

In addition, the investment will strengthen research into emerging treatment areas such as heart failure and renal denervation, a minimally invasive therapy for uncontrolled hypertension.

The acquisition follows Stryker’s earlier move into the vascular intervention market through its approximately US$4.9 billion purchase of Inari Medical in 2025.